Sermorelin
Growth hormone-releasing hormone analogue used in endocrine signalling research.
- Purity:
- ≥99% HPLC
- Sizes available:
- 5 mg – 20 mg
Also known as: NNC 26-0161
| Property | Specification |
|---|---|
| Classification | Pentapeptide GHS-R1a agonist |
| Also known as | NNC 26-0161 |
| Purity | ≥99% HPLC |
| CAS number | 170851-70-4 |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.9 g/mol |
| Vial sizes available | 5 mg, 10 mg, 20 mg |
| Intended use | Supplied after physician review — not an approved medicine |
| Physical form | Lyophilised powder |
| Storage | -20 °C, protected from light |
| Reconstitution | Bacteriostatic water · 3 ml, included at no charge (one per vial) |
| Testing | HPLC + mass spectrometry, per batch |
| Dispatch | Insulated cold-chain, tracked, from Argentina or the United States |
The CoA for the specific batch you would receive is reviewed during your consultation and ships with the material.
Request this batch CoAFrom that lot's certificate of analysis, not from what the supplier asserts. The certificate names the laboratory that took the measurement, the date, the task number, the method and the purity found. PeptoClinic publishes the full reports uncropped, exactly as the laboratory printed them.
It is the report an analytical laboratory issues on a specific sample. Four things are worth checking: which compound it claims to have measured, by what method (HPLC for purity, mass spectrometry for identity), what figure it found, and whether the task number can be verified against the laboratory. A certificate with no verifiable task number is a picture.
Growth hormone-releasing hormone analogue used in endocrine signalling research.
Modified GRF(1-29) tetrasubstituted analogue without drug affinity complex.
Stabilised GHRH(1-44) analogue studied in adipose tissue distribution research.
Supplied after physician review — not an approved medicine